UNH weekly analysis: holds near lows — resistance at $338, support at $332 amid volatility

Traders Union
All News
Financial News
Unitedhealth group slides 2.87% this week

Highlights

The U.S. Senate Judiciary Committee formally investigated UnitedHealth Group’s Medicare Advantage coding practices, targeting in-home nurse visits and physician incentive programs for diagnostic data.
UnitedHealth faces ongoing Senate scrutiny into its nursing home programs while defending its Medicare Advantage cost-saving claims with independent studies during the review period.
Investor focus remains on UnitedHealth’s efforts to sell Optum’s UK business and its upcoming January 27 full-year 2025 earnings report.

Regulatory scrutiny intensifies as Senate probes weigh on investor sentiment

The U.S. Senate Judiciary Committee launched a formal investigation into UnitedHealth Group’s Medicare Advantage risk-adjustment coding practices, scrutinizing measures such as in-home nurse visits and physician incentives for additional diagnostic data. UnitedHealth has responded with independent studies supporting its Medicare Advantage cost-saving claims, while ongoing Senate probes have expanded to examine the company's nursing home programs. The group is also actively seeking the sale of Optum’s UK business and remains under investor focus ahead of its January 27 full-year 2025 earnings report.

Broad-based technical weakness persists as oscillators confirm bearish momentum

On the weekly chart, UNH remains decisively below its MA-20, MA-50, and MA-200 levels, underscoring persistent bearish momentum across all timeframes. The Ichimoku Kijun at $307.83 serves as the closest dynamic support, while MA-20 at $338.24 marks immediate resistance, with additional barriers at $340 and potential support at $332 and $328. Weekly oscillators such as the MACD confirm strong sell signals, while ADX is neutral, suggesting no clear trend strength. RSI and Stoch RSI both display bearish tones with recent oversold signals, CCI is neutral, and BBP reflects former overbought conditions shifting toward renewed selling after a highly volatile week.

Further downside expected as range-bound trading limits rebound potential

Looking ahead, trading is likely to remain choppy with UNH expected to fluctuate between $332.00 and $340.00 over the next 5–7 sessions. The probability of a meaningful rebound is low, making further declines the base-case scenario. A move above the $338–$340 resistance corridor could signal upside toward $345, but a break below $332 would likely accelerate selling toward $328 or even the Ichimoku Kijun support near $308.

Parshwa Turakhiya, analyst, notes that UnitedHealth Group showed definite bearish momentum this week, closing near multi-month lows after a 2.87% decline. He sees persistent negative sentiment as the Senate investigation and ongoing Optum sale remain in focus, amplifying technical weakness under all key averages. UNH is likely to stay volatile between $332.00 and $340.00 in the coming week, with weak rebounds and stronger risks of further selling if $332 is lost. Turakhiya believes that scenario-based tactics remain prudent given shifting investor attention and defensive posturing. "Until price confidently reclaims $338–$340, I favor downside setups and stay patient for signs of stabilization."

Last time we reported that UnitedHealth was exhibiting short- and medium-term momentum, trading above both its 20- and 50-day moving averages while still facing technical resistance at the 200-day level, with technical signals providing a mix of mild buying strength and overbought risks. The price was expected to remain range-bound as bullish momentum stalled, with support and resistance levels highlighted amid ongoing federal investigations, according to technical signals providing a mix of mild buying strength and overbought risks.

Source of Data: UNH Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.